<?xml version='1.0' encoding='utf-8'?>
<document id="25631585"><sentence text="Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor."><entity charOffset="56-67" id="DDI-PubMed.25631585.s1.e0" text="Asunaprevir" /></sentence><sentence text="Asunaprevir (ASV; BMS-650032), a low nanomolar inhibitor of the hepatitis C virus (HCV) NS3 protease, is currently under development, in combination with other direct-acting antiviral (DAA) agents for the treatment of chronic HCV infection"><entity charOffset="0-11" id="DDI-PubMed.25631585.s2.e0" text="Asunaprevir" /><entity charOffset="18-28" id="DDI-PubMed.25631585.s2.e1" text="BMS-650032" /><pair ddi="false" e1="DDI-PubMed.25631585.s2.e0" e2="DDI-PubMed.25631585.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25631585.s2.e0" e2="DDI-PubMed.25631585.s2.e1" /></sentence><sentence text=" Extensive nonclinical and pharmacokinetic studies have been conducted to characterize the ADME properties of ASV" /><sentence text=" ASV has a moderate to high clearance in preclinical species" /><sentence text=" In vitro reaction phenotyping studies demonstrated that the oxidative metabolism of ASV is primarily mediated via CYP3A4; however, studies in bile-duct cannulated rats and dogs suggest that biliary elimination may contribute to overall ASV clearance" /><sentence text=" ASV is shown to have hepatotropic disposition in all preclinical species tested (liver to plasma ratios &gt;40)" /><sentence text=" The translation of in vitro replicon potency to clinical viral load decline for a previous lead BMS-605339 was leveraged to predict a human dose of 2 mg BID for ASV" /><sentence text=" Clinical drug-drug interaction (DDI) studies have shown that at therapeutically relevant concentrations of ASV the potential for a DDI is minimal" /><sentence text=" The need for an interferon free treatment combined with ASV's initial clinical trial data support development of ASV as part of a fixed dose combination for the treatment of patients chronically infected with HCV genotype 1" /><sentence text="" /></document>